Newsroom | 51833 results

MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using lipid nanoparticle delivery to power the next wave of mRNA and gene correction therapeutics, today announced the presentation of clinical data from its RCT1100 PCD inhaled mRNA program at the American Thoracic Society (ATS) 2026 International Conference, held May 15-20, 2026, at the Orange County Convention Center in Orlando, FL. The data represent the first clinical evidence of biological...

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Reflow Medical announces six-month DEEPER CORONARY study results for the Spur® Elute Sirolimus-Eluting Retrievable Stent System at EuroPCR 2026....

LYON, France--(BUSINESS WIRE)--MaaT Pharma Provides an Update on the Application for Marketing Authorization of MaaT013 (Xervyteg®) in the treatment of aGvHD...

ROCHESTER, Minn.--(BUSINESS WIRE)--G-Link is a first-in-class modular adaptor protein technology designed to enable and enhance T-cell-targeting delivery across CAR T workflows....

PARIS--(BUSINESS WIRE)--Regulatory News : GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce que l’ensemble des 28 résolutions soumises au vote de l’Assemblée Générale Mixte des actionnaires, tenue le 19 mai 2026 et présidée par Laurence Rodriguez, Directrice...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders’ vote at the Combined Shareholders’ Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved....

MADISON, Wis.--(BUSINESS WIRE)--FUJIFILM Cellular Dynamics, Inc., a pioneering global developer and manufacturer of human-induced pluripotent stem cells (iPSCs), today celebrated the opening of its new headquarters and iPSC development and manufacturing facility in its Madison home. The new site is expected to quadruple the capacity for the company’s iPSC-based research products and services manufacturing footprint and expand capabilities across FUJIFILM Cellular Dynamics’ research product port...

MENLO PARK, Calif.--(BUSINESS WIRE)--Jupiter Endovascular announced positive results from its SPIRARE II pivotal trial at EuroPCR showing the trial met both of its primary endpoints....

SAARBRÜCKEN, Germany--(BUSINESS WIRE)--New peer-reviewed research published by ki:elements and the PROSPECT-AD consortium demonstrates that the company’s Speech Biomarker for Cognition (SB-C) can reliably detect cognitive impairment and signal underlying Alzheimer’s disease (AD) pathology through an AI voice agent that calls participants at home. The study, involving 736 participants across five independent cohorts in Spain, the UK, Germany and Sweden, is one of the largest and most geographica...

PITTSBURGH--(BUSINESS WIRE)--CytoAgents expanded its Scientific Advisory Board with the appointments of Dr. Michael Wechsler and Dr. Johann Gudjonsson to support pipeline growth....